论文部分内容阅读
Objective: Despite resection with curative intent, a majority of patients with gastric cancer will develop disease recurrence. Postoperative adjuvant chemo-radiotherapy increase the curability of surgery, prevent local recurrence and improve survival. Methods: Between December 2005 and February 2010, 33 patients were eligible for the study, 17 patients were randomly assigned for chemo-radiotherapy (GI) and 16 patients with surgery alone (GII). Patients in GI received chemotherapy (fluorouracil, 425 mg/m2/day, and leucovorin, 20 mg/m2/day, for 5 days) was initiated on day 1 and was followed by chemo-radiotherapy beginning 28 days after the start of the initial cycle of chemotherapy. Chemo-radiotherapy consisted of 4500 cGy of radiation at 180 cGy/day, five days/week for five weeks, with fluorouracil (400 mg/m2/day) and leucovorin (20 mg/m2/day) on the first four and the last four days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg/m2/day) plus leucovorin (20 mg/m2/day) were given one month apart. Results: Grade 3 gastrointestinal toxicity was more common (23.2%) while grade 3 hematological toxicity were (5.8%). Both 3-year survival (53%) and disease free survival (41%) rates were higher in GI than in GII in which they were 43.7% and 31% respectively. Relapse rate was higher in GII (56.3%) than in GI (35.3%). Conclusion: The present study revealed that chemo-radiotherapy after gastric resection in patients with gastric adenocarcinoma improves survival and relapse rates with manageable toxicities. However, studies with larger number of patients are recommended to confirm our results.